Wenying Yang Selected Research

Acarbose

1/2021	Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial.
1/2021	Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes.
5/2019	Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes.
12/2018	Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria.
4/2018	Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial.
11/2017	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
4/2016	Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial.
1/2016	Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
9/2014	Epidemic trend of diabetes in China: For the Xiaoren Pan Distinguished Research Award in AASD.
7/2014	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenying Yang Research Topics

Disease

71	Type 2 Diabetes Mellitus (MODY) 11/2022 - 05/2008
14	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 05/2008
13	Body Weight (Weight, Body) 01/2021 - 04/2012
7	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 04/2012
7	Weight Gain 01/2022 - 05/2008
7	Obesity 01/2022 - 12/2002
6	Hyperglycemia 01/2021 - 01/2014
6	Insulin Resistance 12/2018 - 04/2014
5	Albuminuria 01/2021 - 07/2014
5	Glucose Intolerance 11/2017 - 03/2010
4	Prediabetic State (Prediabetes) 01/2019 - 03/2010
3	Diabetes Mellitus 11/2022 - 01/2019
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2020 - 01/2017
3	Hypertension (High Blood Pressure) 11/2013 - 01/2013
2	Nausea 01/2022 - 01/2021
2	Abdominal Obesity 01/2018 - 07/2014
2	Urinary Tract Infections (Urinary Tract Infection) 08/2017 - 11/2016
2	Infections 08/2017 - 11/2016
2	Weight Loss (Weight Reduction) 11/2016 - 01/2012
1	Pulmonary Tuberculosis 01/2021
1	Vomiting 01/2021
1	Neoplasms (Cancer) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Kidney Diseases (Kidney Disease) 04/2020
1	Heart Failure 04/2020
1	Non-alcoholic Fatty Liver Disease 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2019
1	Hemochromatosis (Bronze Diabetes) 01/2019
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019
1	Cardiomyopathies (Cardiomyopathy) 01/2019
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2019
1	Coronary Disease (Coronary Heart Disease) 11/2017
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 11/2017
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2015
1	Proteinuria 01/2015
1	Overweight 01/2014
1	Drug-Related Side Effects and Adverse Reactions 01/2014
1	Dyslipidemias (Dyslipidemia) 01/2013

Drug/Important Bio-Agent (IBA)

36	Glucose (Dextrose)FDA LinkGeneric 11/2022 - 12/2002
27	Insulin (Novolin)FDA Link 11/2022 - 05/2008
18	Metformin (Glucophage)FDA LinkGeneric 11/2022 - 11/2011
13	Acarbose FDA LinkGeneric 01/2021 - 01/2014
12	Hypoglycemic Agents (Hypoglycemics)IBA 11/2022 - 04/2012
11	Blood Glucose (Blood Sugar)IBA 11/2022 - 05/2008
10	Insulin Glargine (Lantus)FDA Link 01/2022 - 04/2012
10	insulin aspart protamine drug combination 30:70 insulin aspartIBA 04/2019 - 05/2008
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2012
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 01/2014
5	LipidsIBA 01/2019 - 04/2012
4	CreatinineIBA 04/2020 - 04/2016
4	AlbuminsIBA 04/2020 - 04/2016
3	Insulin Aspart (NovoLog)FDA Link 11/2022 - 11/2013
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 01/2012
3	Sitagliptin Phosphate (Januvia)FDA Link 01/2019 - 01/2009
3	dapagliflozinIBA 07/2018 - 11/2016
3	GlucosidasesIBA 11/2017 - 01/2014
3	Insulin Detemir (Levemir)FDA Link 07/2015 - 11/2013
2	insulin aspart drug combination insulin degludecIBA 02/2022 - 01/2019
2	lixisenatideIBA 01/2022 - 01/2018
2	DorzagliatinIBA 01/2022 - 01/2022
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2018
2	LinagliptinIBA 01/2021 - 04/2020
2	Therapeutic UsesIBA 05/2019 - 01/2014
2	Hemoglobins (Hemoglobin)IBA 01/2016 - 01/2014
2	ORALIT (ORS)IBA 01/2014 - 01/2013
2	saxagliptin FDA Link 03/2012 - 11/2011
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2022
1	mazdutideIBA 01/2022
1	dulaglutideIBA 01/2022
1	polyethylene glycol loxenatideIBA 01/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2021
1	Glucagon (Glukagon)FDA Link 01/2021
1	P-2 (P 2)IBA 01/2019
1	Liraglutide FDA Link 01/2019
1	AutoantibodiesIBA 01/2019
1	IronIBA 01/2019
1	Nonsense Codon (Nonsense Mutation)IBA 01/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019
1	Insulin Lispro (Humalog)FDA Link 06/2018
1	InsulinsIBA 06/2018
1	HDL CholesterolIBA 01/2018
1	Isophane Insulin (NPH Insulin)FDA Link 01/2017
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2017
1	Sodium-Glucose Transport ProteinsIBA 11/2016
1	insulin degludecIBA 06/2016
1	Biomarkers (Surrogate Marker)IBA 09/2015
1	VildagliptinIBA 03/2015
1	glimepiride (Amarel)FDA LinkGeneric 03/2015
1	4-toluenesulfonyl fluoride (TSF)IBA 01/2015
1	tangshenIBA 01/2015
1	LDL CholesterolIBA 09/2014
1	serine racemaseIBA 05/2014
1	Alanine Transaminase (SGPT)IBA 01/2013

Therapy/Procedure

19	Glycemic Control 11/2022 - 01/2009
18	Therapeutics 01/2022 - 09/2012
2	Drug Therapy (Chemotherapy) 01/2021 - 01/2012
2	Secondary Prevention 11/2017 - 12/2014
1	Artificial Pancreas 07/2020